Data from two ongoing studies of 1,300 patients with colorectal cancer, the Nurses" Health Study and the Health Professionals Follow-up Study, was analyzed by Harvard scientists with researchers at Massachusetts General Hospital and the Dana-Farber Cancer Institute. After 12 years, the study"s end, 193 (35 percent) deaths and 81 (15 percent) colorectal-cancer-associated deaths were recorded among the 549 patients who regularly used aspirin compared with 287 (39 percent) deaths and 141 (19 percent) colorectal-cancer deaths in the 730 participants who did not use aspirin regularly. There was 47 percent lower risk for dying from the cancer and a 32 percent lower risk for dying prematurely from any cause shown in a group of 719 participants who had not used use aspirin before their cancer diagnosis but who started to take it after their diagnosis. All the patients in the study had surgery for colon cancer and many also had chemotherapy. Participants with COX-2 [cyclooxygenase-2] positive tumors were most likely to benefit from aspirin.
저작권자 © 메디칼업저버 무단전재 및 재배포 금지